ENTITY
Laekna

Laekna (2105 HK)

20
Analysis
Health CareHong Kong
Laekna, Inc. operates as a clinical-stage biotechnology company. The Company researches and develops adenosine triphosphate (ATP) competitive protein kinase B (AKT) inhibitor and androgen synthesis inhibitor. Laekna applies its products for the treatment of ovarian cancer, prostate cancer, breast cancer, and prostate cancer.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x